维普期刊资源整合服务平台（V6.5）

220篇 您的检索式：作者名="VIBERTI G"

选中清除导出查看参考文献查看引证文献引用追踪共11页首页上一页第1页下一页末页 /11 跳转

	题名	作者	年代	出处	被引量
1	Pathogenesis of diabetic nephropathy显示文摘	Raptis AE Viberti G	2001	Exp Clin Endocr Diab2001，109，2：	1
2	Rosiglitazone reduces urinary albumin excretion in type 2 diabetes显示文摘	Bakris G Viberti G Weston WM	2003	J Hum Hypertens2003，17，1：	1
3	Microalbuminuria re- duction with valsartan in patients with type 2 diabetes mellitus:a blood pressure independent effect显示文摘	VIBERTI G WHEELDON NM Microalbuminuria Reduction with Valsartan (MARVAL) Study Investigators	2002	Circulation2002，106，6：	1
4	Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellims: a blood pressure-independent effect 显示文摘	Viberti G Whecldon NM MicroAlbuminuria Reduction With VALsartan (MARVAL) Study investigators	2002	Circulation2002，106，6：	1
5	Rosiglitazone reduces urinary albumin excretion in type Ⅱ diabetes显示文摘	Bakris G Viberti G Weston WM	2003	J Hum Hypertens2003，17，1：	1
6	Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus显示文摘	Hollenberg NK Parving HH Viberti G	2007	J Hypertens2007，25，9：	1
7	Micro-albuminuria and coronary heart disease in NIDDM:An incidence study 显示文摘	Mattock M B Barnes D J Viberti G	1998	Diabetes1998，47，：	1
8	Pathogenesis of diabetic nephropathy显示文摘	Viberti G	2001	Exp clin Endocrinol Diabetes2001，109，：	1
9	Microalbum in uria and cardiovascular risk显示文摘	Kralliedde J Viberti G	2004	Am Hypertens2004，17，10：	1
10	Determinants ofurinary albumin excretion within the normal range in patients withtype 2 diabetes : the Randomised Olmesartan and Diabetes Mi-croalbuminuria Prevention ( ROADMAP) study 显示文摘	RITZ E VIBERTI G C RUILOPE L M	2010	Diabetologia2010，53，1：	1
11	Pathogenesis of diabetic nephropathy显示文摘	Raptis A E Viberti G	2001	Exp Clin Endocrinol Diabetes2001，109，2：	1
12	Mechanical forces in diabetic kidney disease:a trigger for impaired glucose metabolism显示文摘	Gnudi L Thomas SM Viberti G		0，，08：	1
13	Chromogranin A gene expression in non-small cell lung carcinomas显示文摘	Abbona G Papotti M Viberti L	1998	J Pathol1998，186，4：	1
14	Prospectice study of microalbuminuria as predictor of mortality in NIDDM显示文摘	Mettock M B Morrish N J Viberti G C	1992	Diabetes1992，41，：	1
15	Proteinuria in diabetes: bystander or pathway to cardiorenal disease?显示文摘	Karalliedde J Viberti G	2010	J Am Soc Nephrol2010，21，12：	1
16	Atherosclerosis in Type 2 diabetes mellitus and insulin resistance:mechanistic links and therapeutic targets显示文摘	Plutzky J Viberti G Haffner S	2002	J Diabetes Complications2002，16，6：	1
17	Prospective study of microalbu minuria as predictor of mortality in N1DDM 显示文摘	Mattock MB Morrish NJ Viberti G	1992	Diabetes1992，41，6：	1
18	A diabetes outcome progression trial(ADOPT):baseline characteristics of type 2diabetic patients in North America and Europe显示文摘	Viberti G Laehin J Holrman R	2006	Diabet Med2006，23，12：	1
19	Pathogenesis of diabetic nephropathy显示文摘	RAPTIS A E VIBERTI G	2001	Exp Clin Endocrinol Diabetes2001，1092，：	1
20	A Diabetes Outcome Progression (ADOPT):an interational multicenter study of the comparative efficacy of rosiglitazone,glyburide,and metformin in recently diagnosed type 2 diabetes 显示文摘	Viberti G Kabn S Greene DA	2002	Diabetes Care2002，25，：	1

返回顶部每页显示：

共11页首页上一页第1页下一页末页 /11 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示